Plus Therapeutics Announces Selection of “Rhenium (186Re) Obisbemeda” as International Non-Proprietary Name for 186RNL

Rhea-AI Summary

Plus Therapeutics (PSTV) announced that the WHO has assigned the non-proprietary name Rhenium (186Re) obisbemeda to its lead investigational targeted radiotherapeutic, formerly known as 186RNL. This milestone aligns with the company's plans to advance towards mid- and late-stage clinical development, including a Phase 2 trial for recurrent glioblastoma by the end of 2022. The company focuses on innovative treatments for cancer, utilizing advanced liposomal encapsulation technology.

Positive

• World Health Organization assigned a non-proprietary name, indicating progress in drug development.
• Plans to initiate a Phase 2 clinical trial for recurrent glioblastoma by the end of 2022.

Negative

• None.

AUSTIN, Texas, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the World Health Organization’s (WHO) International Non-proprietary Name (INN) Expert Committee has selected the non-proprietary name “Rhenium (¹⁸⁶Re) obisbemeda” for the Company’s lead investigational targeted radiotherapeutic, formerly known as ¹⁸⁶RNL. Going forward, Plus Therapeutics will use Rhenium (¹⁸⁶Re) obisbemeda in place of ¹⁸⁶RNL.

“The assignment of Rhenium (¹⁸⁶Re) obisbemeda as the recommended INN for ¹⁸⁶RNL is another important milestone in the ongoing development of our lead targeted radiotherapeutic as we plan to move it towards mid- and late-stage clinical development, including a planned Phase 2 trial in patients with recurrent glioblastoma by the end of 2022,” said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics.

About Plus Therapeutics

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases. Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of Rhenium (¹⁸⁶Re) obisbemeda including the ability of Rhenium (¹⁸⁶Re) obisbemeda to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-GBM and ReSPECT-LM clinical trials; possible negative effects of Rhenium (¹⁸⁶Re) obisbemeda; the continued evaluation of Rhenium (¹⁸⁶Re) obisbemeda including through evaluations in additional patient cohorts; and the intended functions of the Company’s platform and expected benefits from such functions.

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the cancer diagnostics and therapeutics field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.

Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
Peter.Vozzo@westwicke.com

Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
Terri.Clevenger@westwicke.com

FAQ

What is the new name for Plus Therapeutics' lead investigational drug PSTV?

The World Health Organization has assigned the name Rhenium (186Re) obisbemeda to Plus Therapeutics' lead investigational drug previously known as 186RNL.

What are the next steps for Plus Therapeutics PSTV?

Plus Therapeutics plans to move Rhenium (186Re) obisbemeda into mid- and late-stage clinical development, including a Phase 2 trial for recurrent glioblastoma by the end of 2022.

What does the assignment of a non-proprietary name mean for PSTV?

The assignment of a non-proprietary name is a significant milestone that indicates the drug is progressing through regulatory processes and development stages.